Back to Search
Start Over
Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study.
- Source :
- Open Forum Infectious Diseases; Oct2022, Vol. 9 Issue 10, p1-7, 7p
- Publication Year :
- 2022
-
Abstract
- Background Several studies have reported suboptimal efficacy of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) subtypes endemic to sub-Saharan Africa (SSA) and Southeastern Asia (SEA). The extent of this issue in individuals with human immunodeficiency virus (HIV)/HCV from SSA or SEA residing in Europe is unknown. Methods We retrospectively analyzed data from several prospective European cohorts of people living with HIV. We included individuals with HIV/HCV who originated from SSA or SEA, were treated with interferon-free DAAs, and had an available HCV RNA result ≥12 weeks after the end of treatment. The primary outcome was sustained virological response at least 12 weeks after the end of treatment (SVR<subscript>12</subscript>). Results Of the 3293 individuals with HIV/HCV treated with DAA and with available SVR<subscript>12</subscript> data, 142 were from SSA (n = 64) and SEA (n = 78). SVR<subscript>12</subscript> was achieved by 60 (94% [95% confidence interval {CI}, 86%–98%]) individuals from SSA and 76 (97% [95% CI, 92%–99%]) from SEA. The genotypes of the 6 individuals failing DAA treatment were 2, 3a, 3h, 4a, 4c, and 6j. For 2 of the 4 unsuccessfully treated individuals with available sequence data at treatment failure, NS5A resistance-associated substitutions were present (30R/93S in an individual with genotype 4c and 31M in an individual with genotype 6j). Conclusions SVR<subscript>12</subscript> rates were high in individuals with HIV/HCV residing in Europe and originating from regions where intrinsically NS5A-resistant HCV strains are endemic. HCV elimination for this population in Europe is unlikely to be hampered by suboptimal DAA efficacy. [ABSTRACT FROM AUTHOR]
- Subjects :
- HIV
HEPATITIS C virus
ANTIVIRAL agents
CROSS-sectional method
HIV-positive persons
Subjects
Details
- Language :
- English
- ISSN :
- 23288957
- Volume :
- 9
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Open Forum Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 159980184
- Full Text :
- https://doi.org/10.1093/ofid/ofac508